6533b872fe1ef96bd12d2e92
RESEARCH PRODUCT
Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.
Uwe OttenKlaus HeeseChristoph HockSidonie GolombowskiStefan Rose JohnPia MärzFranz Müller-spahnsubject
MaleModels Molecularmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayCerebrospinal fluidAlzheimer DiseaseMedicineHumansInterleukin 6ReceptorAgedAged 80 and overbiologybusiness.industryInterleukin-6General NeuroscienceNeurodegenerationMiddle Agedmedicine.diseaseGlycoprotein 130Receptors Interleukin-6PathophysiologyCytokineSolubilityImmunologybiology.proteinFemaleAlzheimer's diseasebusinessdescription
We quantitated interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble form of the IL-6 signal-transducing protein gp130 (sgp130) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) (n = 17) and control subjects (n = 18) using sensitive enzyme-linked immunosorbent assays (ELISA). Our results show that none of the parameters examined was significantly different in CSF of AD patients as compared to control age-matched non-demented patients. We conclude that CSF levels of IL-6 and their soluble receptors do not necessarily reflect local changes of the IL-6 system that has been shown to be involved in neurodegenerative events occurring in AD. Levels of sgp130 are substantially high (approximately 100 ng/ml) in the CSF of all individuals probably representing a high antagonistic potential.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1998-04-18 | Neuroscience letters |